US FDA approves nivolumab for adjuvant treatment of resected oesophageal or gastroesophageal junction cancer
Approval for its use in the treatment of residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy is based on results from the Phase III CheckMate-577 trial, in which it prolonged disease-free survival (median 22.4 months v 11.0 months placebo).
Source:
US Food and Drug Administration